Invitrogen Will Focus On Cell-Culture, Stem-Cell Segments in ’08, CEO Says | GenomeWeb
Invitrogen this year will focus on its specialty cell-system business as it seeks to develop its cell-culture and stem-cell technologies on the heels of its acquisition of CellzDirect, CEO Greg Lucier said this week.
The specialty cell-system business is one of five “growth areas” that Invitrogen will focus on in 2008, Lucier said. The other four are emerging markets, cellular analysis, certain instrumentation components, and applied markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.